Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
153 hedge funds and large institutions have $866M invested in Achillion Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 56 reducing their positions, and 23 closing their positions.
290% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $3.62M
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
1% more funds holding
Funds holding: 152 → 153 (+1)
2.37% less ownership
Funds ownership: 84.46% → 82.09% (-2.4%)
18% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 56
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
30% less capital invested
Capital invested by funds: $1.24B → $866M (-$379M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$13.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.93M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.38M |
| 4 |
RI
RTW Investments
New York
|
+$4.17M |
| 5 |
GAM
Gotham Asset Management
New York
|
+$4.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$17.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.56M |
| 4 |
Millennium Management
New York
|
-$7.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.98M |
ACHN Hedge Fund Activity: Q1 2016 in Review
153 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q1 2016, worth a combined $866M — down 30% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ACHN positions and 23 closed out — a net gain of 3 holders — while 46 added to existing stakes and 56 trimmed.
The largest buyer was OrbiMed, adding an estimated $13.7M. The largest seller was Deerfield Management, exiting entirely with an estimated $18M sold.
- 153 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q1 2016, up from 152 in Q4 2015.
- Funds reported $866M of Achillion Pharmaceuticals stock for Q1 2016, down 30% quarter-over-quarter.
- 26 funds opened new Achillion Pharmaceuticals positions in Q1 2016 and 23 closed out, a net change of +3 holders.
- The largest Achillion Pharmaceuticals buyer in Q1 2016 was OrbiMed, an estimated $13.7M added.
- The largest Achillion Pharmaceuticals seller in Q1 2016 was Deerfield Management, an estimated $18M sold.
Based on aggregated 13F filings for Q1 2016.